G1 THERAPEUTICS (NASDAQ:GTHX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.
According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
Separately, Cowen and Company reiterated a “buy” rating on shares of G1 THERAPEUTICS in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $29.75.
G1 THERAPEUTICS (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.48).
ILLEGAL ACTIVITY NOTICE: “G1 THERAPEUTICS (GTHX) Rating Lowered to Sell at Zacks Investment Research” was posted by Stock Observer and is owned by of Stock Observer. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.thestockobserver.com/2017/10/13/g1-therapeutics-gthx-rating-lowered-to-sell-at-zacks-investment-research.html.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Alps Advisors Inc. purchased a new position in G1 THERAPEUTICS during the 2nd quarter valued at approximately $444,000. Victory Capital Management Inc. purchased a new position in G1 THERAPEUTICS during the 2nd quarter valued at approximately $889,000. Goldman Sachs Group Inc. purchased a new position in G1 THERAPEUTICS during the 2nd quarter valued at approximately $1,144,000. Vanguard Group Inc. purchased a new position in G1 THERAPEUTICS during the 2nd quarter valued at approximately $1,291,000. Finally, Chartwell Investment Partners LLC purchased a new position in G1 THERAPEUTICS during the 2nd quarter valued at approximately $1,538,000. Institutional investors and hedge funds own 35.10% of the company’s stock.
About G1 THERAPEUTICS
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.